BERKELEY HEIGHTS, N.J., Feb. 22, 2016 /PRNewswire/ -- Vertice Pharma today announced the appointment of Scott Meyers as Chief Operating Officer.
“We are pleased to welcome Scott to the Vertice Pharma leadership team. Scott brings over 15 years of progressive leadership experience and a strong track record of driving top tier performance. I am confident that Scott will provide immediate leadership and focus to a range of initiatives which will support our growth strategy,” said Don DeGolyer, President & Chief Executive Officer of Vertice Pharma.
“I am delighted to have the opportunity to join a talented leadership team at Vertice Pharma with their commitment to people, customers and growth,” said Mr. Meyers.
Most recently, Scott has served as Vice President and General Manager, Dermatology of Fougera Inc., (a Sandoz / Novartis company). Prior to it, Scott led Strategic Planning & Market Analytics for Sandoz US and worked at McKinsey & Company’s pharmaceutical practice in New Jersey, focusing on R&D and commercial operations. Scott also worked as a Chemical Engineer for Merck at their West Point, PA.
Scott holds a Master of Business Administration from Northwestern University’s Kellogg School of Management and holds a Master of Chemical Engineering, a Bachelor of Science in Chemical Engineering, and a Bachelor of Arts in Chemistry all from Cornell University.
About Vertice Pharma
Vertice Pharma is a specialty pharmaceuticals company focused on improving patients’ health. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies. Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Jersey.
For more information visit www.verticepharma.com
Media Contact:
Vertice Pharma
Kellen Johnson - Kellen.Johnson@verticepharma.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vertice-pharma-appoints-scott-meyers-as-chief-operating-officer-300223496.html
SOURCE Vertice Pharma
